Compare TTRX & LODE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TTRX | LODE |
|---|---|---|
| Founded | 2015 | 1999 |
| Country | United States | United States |
| Employees | 2 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Chemicals |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 281.2M | 290.0M |
| IPO Year | N/A | 2004 |
| Metric | TTRX | LODE |
|---|---|---|
| Price | $9.58 | $4.40 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 2 |
| Target Price | ★ $8.00 | $4.00 |
| AVG Volume (30 Days) | 99.8K | ★ 1.7M |
| Earning Date | 05-31-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 63.55 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,553,796.00 |
| Revenue This Year | N/A | $1,582.85 |
| Revenue Next Year | N/A | $246.20 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.57 | $2.24 |
| 52 Week High | $11.69 | $4.98 |
| Indicator | TTRX | LODE |
|---|---|---|
| Relative Strength Index (RSI) | 72.19 | 56.05 |
| Support Level | $4.40 | $3.61 |
| Resistance Level | N/A | $4.79 |
| Average True Range (ATR) | 1.01 | 0.29 |
| MACD | 0.20 | -0.01 |
| Stochastic Oscillator | 63.17 | 93.39 |
Turn Therapeutics Inc is a clinical-stage biotechnology and medical device development company built around its proprietary platform technology called PermaFusion designed to enhance drug performance. The company is developing non-systemic, non-biologic topical immunomodulators for inflammatory skin disease. Its program, GX-03, is being studied for moderate-to-severe eczema based on preclinical evidence of cytokine inhibition and reduced eczema severity, as well as a favorable real-world tolerability record from prior cleared medical device indications for the same formula. GX-03 is currently being evaluated in an ongoing, randomized, double-blind, vehicle-controlled clinical study designed to assess its potential as a topical treatment for moderate-to-severe eczema.
Comstock Inc commercializes technologies that convert underutilized waste and natural resources into clean energy and supporting products, including electrification, metals, and minerals from end-of-life solar panels. Its subsidiary focuses on producing renewable fuels from waste, energy crops, and woody biomass, supported by facilities in Wisconsin, pilot farms, a biorefinery site in Tulsa, and solar panel recycling operations in Nevada. The Company operates through two high-growth segments and a corporate segment, with its activities grouped into Metals, which generates the majority of revenue, Fuels, Mining, Strategic Investments, and Corporate Services.